Mild COVID-19 Linked to Higher Risk of Type 2 Diabetes
11/08/2025
Clinical summary
Mild COVID‑19 associated with modest short‑term increase in type 2 diabetes
German primary‑care cohort • Rathmann et al., Diabetologia 2022
Summary: A large German primary‑care study found that adults who recovered from mostly mild COVID‑19 had a 28% higher short‑term risk of being newly diagnosed with type 2 diabetes compared with people who had other viral upper respiratory infections.
The elevated risk appeared specific to type 2 diabetes, with no increase seen for other forms of diabetes. The finding was observed in a matched cohort study using the Disease Analyzer primary‑care database and was adjusted for key comorbidities. (Rathmann et al., Diabetologia, 2022)
Research finds mild COVID-19 linked to higher risk of Type 2 Diabetes
Study design and how was included
The research analyzed electronic health records from the Disease Analyzer database, which captures visits to 1,171 general and internal medicine practices across Germany between March 2020 and January 2021. A total of 35,865 adults with a documented COVID-19 diagnosis were matched 1:1 with patients who had acute upper respiratory infections (AURI) unrelated to COVID-19, controlling for age, sex, insurance type, index month, and key comorbidities such as obesity and hypertension. Follow-up continued through July 2021, with a median of 119 days for the COVID-19 group and 161 days for AURI controls. New-onset diabetes was identified using ICD-10 codes E11 (type 2) and E12–E14 (other forms) (Rathmann et al., 2022).
Key findings
Type 2 diabetes incidence was 15.8 per 1,000 person-years in the COVID-19 group versus 12.3 per 1,000 person-years in controls, yielding an incidence rate ratio (IRR) of 1.28 (95% CI 1.05–1.57) after adjustment. No statistically significant increase was seen for other or unspecified diabetes types, and the excess incidence persisted throughout the follow-up window. Importantly, the study population largely comprised non-hospitalized, mild COVID-19 cases, underscoring that even less severe infections may carry metabolic consequences (Rathmann et al., 2022).
Possible mechanisms
Researchers proposed several pathways linking SARS-CoV-2 infection to glycaemia:
Beta-cell injury: The virus can directly infect or inflame pancreatic tissue, disrupting insulin production and secretion.
Post-infection inflammation: Persistent immune activation may drive insulin resistance and worsen glucose regulation.
Lifestyle shifts: Pandemic-related behaviors—reduced physical activity, stress, and dietary changes—may amplify metabolic risk following infection (Rathmann et al., 2022).
These mechanisms may act together, tipping individuals with pre-existing risk factors (e.g., obesity, prediabetes) into overt diabetes.
Clinical implications and recommendations
Even mild COVID-19 could modestly elevate the risk of new-onset type 2 diabetes, warranting awareness and early screening. Clinicians are encouraged to check fasting glucose or HbA1c in patients recovering from COVID-19—particularly those with metabolic risk factors. However, given the short follow-up period, it remains uncertain whether post-COVID diabetes represents a temporary disturbance or the onset of chronic disease. Ongoing monitoring and individualized assessment are advisable (Rathmann et al., 2022).
Limitations and open questions
The study’s median follow-up of ~4 months limits insight into long-term outcomes. Missing BMI data means obesity-related confounding cannot be excluded. Additionally, because the dataset reflects primary-care visits, hospital-based or test-center COVID diagnoses may be underrepresented. Finally, results are based on a German population, so applicability to other regions remains to be confirmed. It also remains unclear whether COVID-19 causes diabetes or simply unmasks undiagnosed cases through stress or inflammation (Rathmann et al., 2022).
Bottom line
Evidence from a large, real-world primary-care cohort suggests that mild COVID-19 can be followed by a modest increase in type 2 diabetes diagnoses. Routine glucose monitoring after recovery—especially in those with obesity, prediabetes, or other metabolic risk factors—is a reasonable precaution, pending longer follow-up to clarify whether this effect is transient or persistent (Rathmann et al., Diabetology, 2022).
